Prostate

Papers
(The median citation count of Prostate is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Overall and progression‐free survival of Afro‐Caribbean men with metastatic castration‐resistant prostate cancer (mCRPC)52
Molecular classification of hormone‐sensitive and castration‐resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens43
Issue Information38
34
The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially‐Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histo33
The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate30
The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer28
The Diagnostic Value of Plasma Small Extracellular Vesicle‐Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models27
Bipolar androgen therapy for treatment of metastatic castration‐resistant prostate cancer: A case series26
VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach25
25
Issue Information24
Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate23
23
Issue Information23
Clinical significance of unfavorable findings in intermediate‐risk prostate cancer patients for predicting treatment outcomes after contemporary, dose‐escalated multimodal radiotherapy21
Prognostic value of neutrophil‐to‐lymphocyte ratio in patients with metastatic castration‐resistant prostate cancer receiving prostate‐specific membrane antigen targeted radionuclide therapy20
Germline genetics of prostate cancer20
Issue Information19
Issue Information19
Issue Information19
18
Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins18
Issue Information17
Continuity of care in acute survivorship phase, and short and long‐term outcomes in prostate cancer patients17
Issue Information17
Issue Information17
Progression‐Free Survival Prediction Performance of ChatGPT: Analysis With Real Life Data in Early and Locally Advanced Prostate Cancer17
P‐score in preoperative biopsies accurately predicts P‐score in final pathology at radical prostatectomy in patients with localized prostate cancer16
16
AT‐rich interaction domain 5A regulates the transcription of interleukin‐6 gene in prostate cancer cells16
Safety and Efficacy of Intra‐Prostatic Injection of Betamethasone for Refractory Chronic Nonbacterial Prostatitis: A Prospective Cohort Clinical Study16
Development of a nomogram combining multiparametric magnetic resonance imaging and PSA‐related parameters to enhance the detection of clinically significant cancer across different region16
Issue Information16
Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐cente15
Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa15
Diagnostic potential of SDHB mRNA contained in serum extracellular vesicles among patients with prostate cancer15
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality15
Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy15
Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy15
Racial Disparities in Future Development of Lethal Prostate Cancer Based on Midlife Baseline Prostate‐Specific Antigen15
Response to the Letter to the Editor15
Does surgery benefit patients with oligometastatic or metastatic prostate cancer? – A retrospective cohort study and meta‐analysis15
Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacoth15
Immune mechanisms behind prostate cancer in men of African ancestry: A review15
A novel prognostic model predicting overall survival in patients with metastatic castration‐resistant prostate cancer receiving standard chemotherapy: A multi‐trial cohort analysis14
Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment14
Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients14
Survival after radical prostatectomy versus radiation therapy in clinical node‐positive prostate cancer14
Response to the letter to the editor: “Don't throw the baby out with the bath water” by Horsley et al.14
Development and internal validation of a nomogram predicting significant prostate cancer: Is it clinically applicable in low prevalent prostate cancer countries? A multicenter study14
Restoration of erectile function by a combination of antiapoptosis by JNK inhibitor and preservation of smooth muscle or endothelium by hepatocyte growth factor in a rat model of cavernous nerve injur14
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer14
Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: Results from a multicenter radical prostatectomy cohort13
Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer13
Prospective role of 3βHSD1 in prostate cancer precision medicine13
Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy13
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level13
Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL‐17 signaling pathway gene LCN2 in castration‐resistant prostate cancer12
Non‐cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy12
Upregulation of TLR5 indicates a favorable prognosis in prostate cancer12
Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population12
Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities12
Nanomechanical‐based classification of prostate tumor using atomic force microscopy12
Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer11
PSA density does not improve predictive accuracy of the UCSF‐CAPRA score11
Modified female mid‐urethral sling for the treatment of incontinence after prostate treatment: One‐center experience11
Effect of positive surgical margins at radical prostatectomy on cancer‐specific mortality in high/very high‐risk prostate cancer patients with Gleason Grade Group 4–511
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy11
Pathological significance and prognostic role of LATS2 in prostate cancer11
Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer11
SLX4IP N‐terminus dictates telomeric localization in ALT‐like castration‐resistant prostate cancer cell lines11
Long‐term outcomes of Holmium laser enucleation of prostate and predictive model for symptom recurrence10
Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients10
Assessment of the optimal number of positive biopsy cores to discriminate between cancer‐specific mortality in high‐risk versus very high‐risk prostate cancer patients10
Feasibility, acceptability, and behavioral outcomes of a multimodal intervention for prostate cancer patients: Experience from the MARTINI lifestyle program10
Re: Impact of mpMRI targeted biopsy on intraoperative nerve‐sparing (NeuroSAFE) during robot‐assisted laparoscopic radical prostatectomy10
Maternal diet during gestation affect prostatic tissue component in SHR/Izm offspring10
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models10
A matter of size? Health‐related quality of life after radical prostatectomy for patients with giant prostates10
Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia9
Test–retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer9
18F‐FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis9
The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI‐RADS 3 lesions on multiparametric magnetic resonance imaging9
Clinical and histopathological parameters in transrectal ultrasound‐guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups9
Does size matter? A single institution's comparison of Aquablation in prostates greater than or less than 150 mL9
Clinical, pathologic, and molecular features of amphicrine prostate cancer9
LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study9
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series9
Proton therapy for high‐risk prostate cancer: Results from the Proton Collaborative Group PCG 001‐09 prospective registry trial9
Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients9
Translation and validation of a lifestyle questionnaire related to prostate cancer9
MiLEP Will be the New Goldstandard Procedure for BPH Treatment9
CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation9
Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial9
Influence of microbiome in intraprostatic inflammation and prostate cancer9
Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system9
Physician knowledge, practice patterns, and barriers encountered regarding guideline‐concordant use of bone modifying agents for prostate cancer9
Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis8
Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound8
Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population8
Increased α2,3‐sialyl N‐glycosylated prostate‐specific membrane antigen (PSMA) in post‐DRE urine is associated with high grade group prostate cancer8
Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer8
Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association8
ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis8
Barriers and facilitators of germline genetic evaluation for prostate cancer8
Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level8
Impact of median lobe on urinary function after robotic prostatectomy8
The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups8
8
Expression and immune infiltration studies of IL‐33‐ST2‐NF‐κB signaling pathway in prostate cancer8
Single‐port versus multiport robotic‐assisted radical prostatectomy: A systematic review and meta‐analysis on the da Vinci SP platform8
Assessing the Impact of Transition and Peripheral Zone PSA Densities Over Whole‐Gland PSA Density for Prostate Cancer Detection on Multiparametric MRI8
Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery following radical prostatectomy: A randomized clinical trial8
Postoperative functional and cancer control evaluation of conventional and Retzius‐sparing robot‐assisted radical prostatectomy: Comparison of selected cases by propensity score matching8
Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis8
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review8
IL‐8 protects prostate cancer cells from GSK‐3β‐induced oxidative stress by activating the mTOR signaling pathway8
Real‐world evidence of 18F‐fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System8
PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications8
PSMA‐heterogeneity in metastatic castration‐resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy8
RETRACTION: Interleukin‐6 Protects LNCaP Cells From Apoptosis Induced by Androgen Deprivation Through the Stat3 Pathway8
Issue Information8
Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?8
Prospective study of diagnostic accuracy in the detection of high‐grade prostate cancer in biopsy‐naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test8
Tissue clearing techniques for three‐dimensional optical imaging of intact human prostate and correlations with multi‐parametric MRI8
The activated complement pathway in the fibrous process of benign prostatic hyperplasia7
7
7
Issue Information7
Letter to the Editor: “Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients”7
Issue Information7
Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience7
Issue Information7
Quality of life after robotic‐assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP‐01)7
Issue Information7
Socioeconomic Disparities in Prostate Cancer Treatment: The Impact of Area Deprivation Index on Initial Treatment Type for Localized PCa in a North‐American Cohort7
Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy7
Ultrasound‐based radiomics score for pre‐biopsy prediction of prostate cancer to reduce unnecessary biopsies7
Issue Information7
Issue Information7
7
Issue Information7
Expression of high molecular weight cytokeratin—A novel feature of aggressive and innate hormone‐refractory prostatic adenocarcinoma7
Evaluation of online teaching modules for PSMA PET interpretation7
Current and projected number of years of life lost due to prostate cancer: A global study7
7
Translation, Cross‐Cultural Adaptation, and Psychometric Validation of the Turkish Version of the “Expanded Prostate Cancer Index Composite (EPIC)” in Prostate Cancer Patients7
Phenotypic characterization of two novel cell line models of castration‐resistant prostate cancer7
7
Issue Information7
Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side‐specific negative lymph node metastasis at radical prostatectomy6
PSA provocation by bipolar androgen therapy may predict duration of response to first‐line androgen deprivation: Updated results from the BATMAN study6
In Vivo Efficacy of a Macrocyclic Peptoid‐Peptide Hybrid That Selectively Modulates the Beta‐Catenin/TCF Interaction to Inhibit Prostate Cancer6
Genetic polymorphisms at 19q13.33 are associated with [−2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer6
6
Clinical outcomes in patients with metastatic castrate‐resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case–control study6
Based on PI‐RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4−20 ng/mL6
Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort6
Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer6
CHARGE: The “Big Questions” in Prostate Cancer for 20246
Evaluation of initial prostate cancer biopsies utilizing 3D open‐top light‐sheet microscopy for detection of early disease6
Is prostatic adenocarcinoma detectable by urine cytology—A multicenter retrospective review6
Impact of comorbidities on prostate cancer‐specific mortality: A population‐based cohort study6
Pilot study of the diagnostic utility of 89Zr‐df‐IAB2M and 68Ga‐PSMA‐11 PET imaging and multiparametric MRI in localized prostate cancer6
Cover Image: Volume 82 Issue 86
6
Intermediate‐term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score6
3βHSD activity saturates at physiological substrate concentrations in intact cells6
Therapeutic effects of β‐caryophyllene on proliferative disorders and inflammation of the gerbil prostate6
Assessing state‐of‐the‐art online large language models for patient education regarding prostatitis6
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness6
Risk factors for bladder neck contracture after transurethral resection of the prostate6
Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron‐sulfur protein 3, a mitochondrial protein essenti6
Chronic coexposure to arsenic and estrogen potentiates genotoxic estrogen metabolic pathway and hypermethylation of DNA glycosylase MBD4 in human prostate epithelial cells6
6
6
Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer6
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki676
Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides6
Clinical study of multifactorial diagnosis in prostate biopsy6
Tumorigenic transformation of human prostatic epithelial cell line RWPE‐1 by growth hormone‐releasing hormone (GHRH)6
Analysis of three primary prostatic sarcoma cases and literature review6
Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratificatio6
Biological role of fructose in the male reproductive system: Potential implications for prostate cancer5
Impact of prostate biopsy secondary pathology review on radiotherapy management5
Therapeutic effects of nerve growth factor‐targeting therapy on bladder overactivity in rats with prostatic inflammation5
Investigation of pelvic floor influence on prostate displacement in image‐guided radiotherapy5
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study5
Bipolar androgen therapy (BAT): A patient's guide5
Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan5
Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings5
The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms5
An Australian experience using Tc‐PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy5
Evaluation of a photodynamic therapy agent using a canine prostate cancer model5
Development and validation of a nomogram for predicting osteoporosis in prostate cancer patients: A cross‐sectional study from China5
Don't throw the baby out with the bath water5
Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis5
Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer5
Protein signatures to distinguish aggressive from indolent prostate cancer5
Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix5
Cover Image: Volume 82 Issue 65
Total‐, LDL‐, and HDL‐cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study5
Smoothened loss is a characteristic of neuroendocrine prostate cancer5
Predicting clinically significant prostate cancer in elderly patients: A nomogram approach with shear wave elastography5
Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics5
Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer5
Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma5
Characterization of tumor‐associated macrophages in prostate cancer transgenic mouse models5
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA‐targeted radioligand therapy5
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide5
Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real‐life experience of ADT in Asia (READT) study5
Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer5
High‐intensity interval training attenuates the effects caused by arterial hypertension in the ventral prostate5
Inhibition of human prostate smooth muscle contraction by the inhibitors of protein kinase C, GF109203X, and Go69835
Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel‐resistant prostate cancer5
A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer5
Post‐diagnostic metformin and statin use and risk of biochemical recurrence in Veterans diagnosed with prostate cancer5
Combined 177Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing t4
Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer4
Screening for Predictive Factors of Efficacy of Second‐Generation Androgen Receptor Axis‐Targeted Agents in Patients With High‐Risk Metastatic Hormone‐Sensitive Prostate Cancer4
Trends in prostate cancer incidence among Black men in the Caribbean and the United States4
The 28th Annual Prostate Cancer Foundation Scientific Retreat report4
Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer4
Issue Information4
Issue Information4
Clinical parameters and nomograms for predicting lymph node metastasis detected with 68Ga‐PSMA‐PET/CT in prostate cancer patients candidate to definitive radiotherapy4
Minimally invasive surgical therapies for benign prostatic hyperplasia in the geriatric population: A systematic review4
Sociodemographic index and global trends in prostate cancer: 1990–20174
Functional outcome after radical prostatectomy in 1313 patients: A single‐center study4
Impact of definitive radiotherapy on metabolic response measured with 68Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer4
Clinical and genomic features of SPOP‐mutant prostate cancer4
Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis4
Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity4
Rapid and Deep Prostate‐Specific Antigen Decline is a Prognostic Marker in Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Multi‐Intuitional Analysis4
Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer4
Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling4
Comparison of 68Ga‐PSMA PET/CT and mp‐MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study4
The role of transurethral resection of prostate (TURP) in patients with underactive bladder: 12 months follow‐up in different grades of detrusor contractility4
Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer4
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer4
RETRACTION: Interleukin‐4 Activates Androgen Receptor Through CBP/p3004
RETRACTION: Stat3 Enhances the Growth of LNCaP Human Prostate Cancer Cells in Intact and Castrated Male Nude Mice4
The effect of tranexamic acid on perioperative blood loss in transurethral resection of the prostate: A double‐blind, randomized controlled trial4
4
An update on the current status and future prospects of erectile dysfunction following radical prostatectomy4
4
Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer4
The Prostate Microbiome Is Associated With Prostate Size and PSA Level, Independent of Age, in BPH Patients4
Diagnostic performance of microUltrasound at MRI‐guided confirmatory biopsy in patients under active surveillance for low‐risk prostate cancer4
0.1597900390625